Unlike EGFR and HER2 inhibitors that target receptor tyrosine kinases located on the cell surface, ALK, BRAF/MEK, and PI3K/AKT/mTOR inhibitors act on non-receptor kinases in intracellular signaling pathways critical for cancer cell proliferation and survival [103,104]. Here, ERBB2 is linked to cancer.